SCHEMBL1366503

SCHEMBL1366503

O=C(/C=C/c1ccc(Cl)cc1Cl)c1cc2c(Br)cc(Br)cc2[nH]c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.50
▸ LMNA P02545 6/20 0.50
▸ KMT2A Q03164 5/20 0.50
▸ ALDH1A1 P00352 5/20 0.50
▸ RAB9A P51151 4/20 0.50
▸ POLB P06746 3/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ MCL1 Q07820 2/20 0.50
▸ STAT3 P40763 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ PTPN5 P54829 1/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ L3MBTL1 Q9Y468 3/20 0.48
▸ GAA P10253 3/20 0.48
▸ TP53 P04637 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348764 1.00 MAPT (0.50) MAPTLMNAKMT2AALDH1A1RAB9A
SCHEMBL1366505 1.00 MAPT (0.50) MAPTLMNAKMT2AALDH1A1RAB9A
SCHEMBL1366558 0.85 STAT3 (0.47) MAPTLMNAKMT2AALDH1A1POLB
SCHEMBL1369063 0.85 STAT3 (0.47) MAPTLMNAKMT2AALDH1A1POLB
SCHEMBL1366557 0.85 STAT3 (0.47) MAPTLMNAKMT2AALDH1A1POLB
SCHEMBL4342584 0.79 PTPN5 (0.54) MAPTLMNAKMT2AALDH1A1RAB9A
SCHEMBL4342226 0.79 PTPN5 (0.54) MAPTLMNAKMT2AALDH1A1RAB9A
SCHEMBL4342230 0.79 PTPN5 (0.54) MAPTLMNAKMT2AALDH1A1RAB9A
SCHEMBL1367904 0.78 MAPT (0.62) MAPTLMNAKMT2AALDH1A1RAB9A
SCHEMBL4351326 0.78 MAPT (0.62) MAPTLMNAKMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 — — US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 — — WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 — — US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS MAPT 4718/4885LMNA 1399/4885KMT2A 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback